rHuPH20 + zoledronic acid
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Risk Factors for or a Diagnosis of Osteoporosis
Conditions
Risk Factors for or a Diagnosis of Osteoporosis
Trial Timeline
Dec 1, 2008 → Sep 21, 2009
NCT ID
NCT00807963About rHuPH20 + zoledronic acid
rHuPH20 + zoledronic acid is a phase 1 stage product being developed by Halozyme Therapeutics for Risk Factors for or a Diagnosis of Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00807963. Target conditions include Risk Factors for or a Diagnosis of Osteoporosis.
What happened to similar drugs?
0 of 20 similar drugs in Risk Factors for or a Diagnosis of Osteoporosis were approved
Approved (0) Terminated (2) Active (18)
🔄olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
6
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00807963 | Phase 1 | Completed |
Competing Products
20 competing products in Risk Factors for or a Diagnosis of Osteoporosis